Pipeline

Rain has built a pipeline of targeted oncology therapies. For more information on each of our programs, please visit our Science page.

Program Overview

Program	Indication	Combo Strategy	Preclinical LO IND ES	Dose Escalation Ph 1a	Dose Expansion Ph 1b Ph 2	Pivotal Ph 2b Ph 3
RAIN-32 (DS-3032) MDM2	WD / DD Liposarcoma	–				2021 Start
	MDM2 Basket Study	–			2021 Start
	AML: FLT3-ITD	Quizartinib
Tarloxotinib Pan-HER	NSCLC: HER2 Ex20	–
	Basket: NRG1 / HER Fusions1	–
RAD52 Research Program	PARP-relapsed. HRD+Tumors	–
	BRCA-deficient tumors	–

Program	Indication / Strategy	Phase
RAIN-32 (DS-3032) MDM2	WD / DD Liposarcoma	Phase 2
	MDM2 Basket Study	Phase 1a
	AML: FLT3-ITD / Quizartinib	Phase 1a
Tarloxotinib Pan-HER	NSCLC: HER2 Ex20	Phase 2
	Basket: NRG1 / HER Fusions1	Phase 2
RAD52 Research Program	PARP-relapsed. HRD+Tumors	Preclinical
	BRCA-deficient tumors	Preclinical

		Discovery	Preclinical	Phase 1	Phase 2
NSCLC	HER2 Ex20Ins EGFR Ex20Ins Relapsed (Monotherapy)
Pan-Tumor	NRG / HER Fusions1 Relapsed (Monotherapy)
Pan-Tumor	HER2 Mutant Relapsed (Monotherapy)

Trial recruiting

1. Includes EGFR kinase domain duplications (KDD), EGFR fusions, ERBB2, and ERBB4 fusions